Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1′-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry

AbstractThe benzodiazepine midazolam is a probe drug used to phenotype cytochrome P450 3A activity. In this situation, effective sedative concentrations are neither needed nor desired, and in fact the use of very low doses is advantageous. We therefore developed and validated an assay for the femtomolar quantification of midazolam and 1′-hydroxymidazolam in human plasma. Plasma (0.25 mL) and 96-well-based solid-phase extraction were used for sample preparation. Extraction recoveries ranged between 75 and 92% for both analytes. Extracts were chromatographed within 2 min on a Waters BEH C18 1.7 μm UPLC® column with a fast gradient consisting of formic acid, ammonia, and acetonitrile. Midazolam and 1′-hydroxymidazolam were quantified using deuterium- and 13C-labeled internal standards and positive electrospray tandem mass spectrometry in the multiple reaction monitoring mode, which yielded lower limits of quantification of 50 fg/mL (154 fmol/L) and 250 fg/mL (733 fmol/L) and a corresponding precision of <20%. The calibrated concentration ranges were linear for midazolam (0.05–250 pg/mL) and 1′-hydroxymidazolam (0.25–125 pg/mL), with correlation coefficients of >0.99. Within-batch and batch-to-batch precision in the calibrated ranges for both analytes were <14% and <12%. No ion suppression was detectable, and plasma matrix effects were minimized to <15% (<25%) for midazolam (1′-hydroxymidazolam). The assay was successfully applied to assess the kinetics of midazolam in two human volunteers after the administration of single oral microgram doses (1–100 μg). This ultrasensitive assay allowed us to quantify the kinetics of midazolam and 1′-hydroxymidazolam for at least 10 h, even after the administration of only 1 μg of midazolam. FigureUPLC/MS/MS quantification of femtomolar midazolam plasma concentrations

[1]  Li Li,et al.  Development and validation of a LC-MS/MS method based on a new 96-well Hybrid-SPE™-precipitation technique for quantification of CYP450 substrates/metabolites in rat plasma , 2011, Analytical and bioanalytical chemistry.

[2]  W. Haefeli,et al.  Determining the Time Course of CYP3A Inhibition by Potent Reversible and Irreversible CYP3A Inhibitors Using A Limited Sampling Strategy , 2011, Clinical pharmacology and therapeutics.

[3]  A. McLachlan,et al.  A High-Throughput Assay Using Liquid Chromatography-Tandem Mass Spectrometry for Simultaneous In Vivo Phenotyping of 5 Major Cytochrome P450 Enzymes in Patients , 2009, Therapeutic drug monitoring.

[4]  D. Breimer,et al.  A 'cocktail' strategy to assess in vivo oxidative drug metabolism in humans. , 1990, Trends in pharmacological sciences.

[5]  Honghui Zhou,et al.  “Cocktail” Approaches and Strategies in Drug Development: Valuable Tool or Flawed Science? , 2004, Journal of clinical pharmacology.

[6]  F. Akhlaghi,et al.  Development and validation of a rapid and sensitive assay for simultaneous quantification of midazolam, 1'-hydroxymidazolam, and 4-hydroxymidazolam by liquid chromatography coupled to tandem mass-spectrometry. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[7]  T. Annesley Ion suppression in mass spectrometry. , 2003, Clinical chemistry.

[8]  Elizabeth Landrum Michalets,et al.  Update: Clinically Significant Cytochrome P‐450 Drug Interactions , 1998, Pharmacotherapy.

[9]  F Peter Guengerich,et al.  Cytochromes P450, drugs, and diseases. , 2003, Molecular interventions.

[10]  K. Verbeke,et al.  A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1'-hydroxymidazolam and 4-hydroxymidazolam in human plasma. , 2011, Biomedical chromatography : BMC.

[11]  X. Boulenc,et al.  Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. , 2009, British journal of clinical pharmacology.

[12]  T. Olah,et al.  The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. , 1999, Rapid communications in mass spectrometry : RCM.

[13]  Nicholas B Tiscione,et al.  Quantitation of benzodiazepines in whole blood by electron impact-gas chromatography-mass spectrometry. , 2008, Journal of analytical toxicology.

[14]  K. Linnet,et al.  A validated method for simultaneous screening and quantification of twenty-three benzodiazepines and metabolites plus zopiclone and zaleplone in whole blood by liquid-liquid extraction and ultra-performance liquid chromatography- tandem mass spectrometry. , 2010, Journal of analytical toxicology.

[15]  Wei Zhang,et al.  Simultaneous determination of tolbutamide, omeprazole, midazolam and dextromethorphan in human plasma by LC-MS/MS--a high throughput approach to evaluate drug-drug interactions. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[16]  S. Lutz-Bonengel,et al.  Cocktail Approach for In Vivo Phenotyping of 5 Major CYP450 Isoenzymes: Development of an Effective Sampling, Extraction, and Analytical Procedure and Pilot Study With Comparative Genotyping , 2012, Journal of clinical pharmacology.

[17]  F. Tse,et al.  Simultaneous determination of midazolam and 1'-hydroxymidazolam in human plasma by liquid chromatography with tandem mass spectrometry. , 2007, Biomedical chromatography : BMC.

[18]  L. Bertilsson,et al.  The karolinska cocktail for phenotyping of five human cytochrome P450 enzymes , 2003, Clinical pharmacology and therapeutics.

[19]  E. Sellers,et al.  Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N‐acetyltransferase‐2, and xanthine oxidase activities with the “Cooperstown 5+1 cocktail” , 2003, Clinical pharmacology and therapeutics.

[20]  S. Athanaselis,et al.  Development and validation of an EI-GC-MS method for the determination of benzodiazepine drugs and their metabolites in blood: applications in clinical and forensic toxicology. , 2010, Journal of pharmaceutical and biomedical analysis.

[21]  D. Greenblatt,et al.  Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase. , 2009, British journal of clinical pharmacology.

[22]  H. Kokki,et al.  Determination of midazolam and 1-hydroxymidazolam from plasma by gas chromatography coupled to methane negative chemical ionization mass spectrometry after sublingual administration of midazolam. , 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[23]  G. McMillin,et al.  Quantitation of benzodiazepines in urine, serum, plasma, and meconium by LC-MS-MS. , 2008, Journal of analytical toxicology.

[24]  S. Krähenbühl,et al.  Determination of midazolam and its hydroxy metabolites in human plasma and oral fluid by liquid chromatography/electrospray ionization ion trap tandem mass spectrometry. , 2007, Rapid communications in mass spectrometry : RCM.

[25]  M. H. Ensom,et al.  Clinical Pharmacokinetic Monitoring of Midazolam in Critically Ill Patients , 2007, Pharmacotherapy.

[26]  Malcolm Rowland,et al.  Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs , 2006, Clinical pharmacology and therapeutics.

[27]  B. Matuszewski,et al.  Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. , 2003, Analytical chemistry.